Organizations Filed Purposes:
THE MISSION OF THE INSTITUTE FOR IN VITRO SCIENCES IS:- TO DRIVE THE OPTIMIZATION AND APPLICATION OF SCIENTIFICALLY ROBUST IN VITRO METHODS THAT ARE ACCEPTED BY REGULATORY AGENCIES AND ADOPTED BY INDUSTRY WORLDWIDE.- TO CREATE A FORUM IN WHICH INDUSTRY, REGULATORY AGENCIES AND ANIMAL WELFARE ORGANIZATIONS CAN WORK TOGETHER TO DEVELOP HUMANE SCIENTIFIC TOOLS FOR TESTING.- TO UTILIZE OUR EXPERTISE TO CREATE EDUCATIONAL AND OUTREACH PROGRAMS THAT WILL EXPAND THE ADOPTION OF NON-ANIMAL TEST METHODS AROUND THE GLOBE.
TO INCREASE THE USE AND ACCEPTANCE OF NON-ANIMAL TEST METHODS WORLDWIDE.
SCIENCE PROGRAM: IIVS WORKED WITH MORE THAN ONE HUNDRED COMPANIES TO DETERMINE THE APPROPRIATE NON-ANIMAL TESTING STRATEGIES, CONDUCTED TESTING AND ASSISTED IN INTERPRETATION OF DATA. OVER ELEVEN HUNDRED COMPOUNDS/PRODUCTS WERE TESTED AT THE IIVS LABORATORY - MANY IN MORE THAN ONE TEST. IIVS CONTINUES TO OPTIMIZE AND STANDARDIZE IN VITRO METHODS TO MAKE THEM SUITABLE FOR INDUSTRY AND REGULATORY NEEDS. ADVANCEMENTS ARE SHARED WITH THE SCIENTIFIC COMMUNITY THROUGH PRESENTATIONS AND PUBLICATIONS SO THAT OTHER INDUSTRY AND REGULATORY SCIENTISTS CAN BENEFIT. IN 2019 IIVS SUCCESSFULLY COMPLETED THE RING TRIAL OF A NEW TEST FOR SKIN SENSITIZATION. THE RESULTS OF THE RING TRIAL HAVE BEEN PUBLISHED AND THE METHOD HAS BEEN PUT FORWARD TO THE ORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT (OECD) FOR CONSIDERATION IN ITS TEST GUIDELINE PROGRAM. THE IIVS RESPIRATORY PROGRAM HAS EXPANDED SIGNIFICANTLY INTO THE PERSONAL CARE/HOUSE HOLD PRODUCT SECTOR WITH THE ADDITION OF AN EXPOSURE CHAMBER WHICH MIMICS HUMAN EXPOSURE TO INHALED MATERIALS. THIS HAS ALLOWED FOR TESTING IN THESE NEW INDUSTRY SECTORS. IIVS SUCCESSFULLY COMPLETED TESTING THE PROFICIENCY CHEMICALS FOR A NEW SKIN SENSITIZATION TEST WHICH ALLOWS FOR THE TESTING OF INSOLUBLE MATERIALS OR FINAL FORMULATIONS.
EDUCATION AND OUTREACH PROGRAM: IIVS PROVIDES TRAINING TO A VARIETY OF STAKEHOLDERS INCLUDING INDUSTRY AND REGULATORY SCIENTISTS AND ANIMAL PROTECTION ORGANIZATIONS. THESE TRAININGS ARE TAILORED FOR THE PARTICIPANTS AND GENERALLY INCLUDE LECTURES, HANDS-ON DEMONSTRATIONS AND DATA INTERPRETATION. IIVS HAS A FOCUSED PROGRAM TO HELP CHINESE REGULATORS LEARN ABOUT AND ADOPT IN VITRO METHODS TO REDUCE THEIR RELIANCE ON ANIMALS FOR TESTING OF COSMETICS. FOR THIS PROGRAM, IIVS STAFF MADE EIGHT TRIPS TO CHINA WHICH INCLUDED A HANDS-ON TRAINING AND MULTIPLE PRESENTATIONS AT UNIVERSITIES AND CONFERENCES. IIVS CONTINUES TO HOLD ANNUAL HANDS-ON TRAINING COURSES WHICH ARE ATTENDED BY SCIENTISTS THROUGHOUT THE WORLD, INCLUDING EUROPE, ASIA AND SOUTH AMERICA. IIVS SCIENTISTS WERE INVITED TO PARTICIPATE IN EXPERT PANELS CONVENED BY THE ORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT (OECD) WHICH HARMONIZES IN VITRO TESTING APPROACHES FOR THE WORLDWIDE SCIENTIFIC COMMUNITY. THESE PANELS DISCUSSED NEW METHODS FOR GENETIC TOXICOLOGY, SKIN SENSITIZATION, EYE IRRITATION AND SKIN CORROSION. IIVS IS LEADING EFFORTS WITH INDUSTRY CONSORTIA AND 2 DIVISIONS OF THE US FDA TO APPLY NON-ANIMAL METHODS FOR SPECIFIC ENDPOINTS. IIVS IS ALSO INVOLVED IN EFFORTS TO SUPPORT THE US EPA'S GOAL TO REDUCE RELIANCE ON ANIMAL MODELS. IIVS STAFF HOLD BOARD POSITIONS WITHIN SOCIETIES THAT HAVE THE MISSION TO WORK COLLABORATIVELY TO INCREASE THE USE AND ACCEPTANCE OF ALTERNATIVE METHODS, SUCH AS THE AMERICAN SOCIETY FOR CELLULAR AND COMPUTATIONAL TOXICOLOGY, THE EUROPEAN SOCIETY FOR TOXICOLOGY IN VITRO, THE US SOCIETY OF TOXICOLOGY AND THE CHINESE SOCIETY OF TOXICOLOGY. IIVS RECEIVED A SMALL CONFERENCE GRANT FROM THE US FDA TO CONTINUE A SERIES OF WORKSHOPS OF APPROACHES IN GENETIC TOXICOLOGY FOR TOBACCO PRODUCTS. THE WORKSHOPS ARE ATTENDED BY MEMBERS OF INDUSTRY, TESTING/RESEARCH FACILITIES AND THE REGULATORY AGENCY. RESULTS OF THE FIRST WORKSHOP WERE PUBLISHED IN A PEER-REVIEWED JOURNAL.IIVS PROMOTED THE USE OF A 3D TISSUE CONSTRUCT FOR PHOTOTOXICITY APPLICATIONS AT THE OECD. THIS TEST WOULD COMPLEMENT THE STANDARD TEST BY BEING ABLE TO TEST COMPOUNDS THAT ARE INSOLUBLE (AND THUS NOT COMPATIBLE WITH THE STANDARD TEST).IIVS CONTINUED ITS COLLABORATIVE PROJECT WITH MANUFACTURERS OF PERSONAL LUBRICANTS UNDER THE FDA CENTER FOR DEVICES AND RADIOLOGICAL HEALTH'S (CDRH) PROGRAM MEDICAL DEVICE DEVELOPMENT TOOL (MDDT). A SUCCESSFUL VALIDATION WILL RESULT IN THE REPLACEMENT OF A RECOMMENDED ANIMAL TEST WITH A HUMAN CELL-BASED MODEL.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Hans A Raabe | CHIEF OPERATING OFFICER/TREASURER | 40 | $144,773 |
| Holger P Behrsing | PRINCIPAL SCIENTIST | 40 | $136,303 |
| Erin H Hill | PRESIDENT/BOARD MEMBER | 40 | $132,769 |
| Gertrude-Emilia Costin | DIRECTOR, LABORATORY SERVICES | 40 | $118,534 |
| Brent J Gilbert | BUSINESS DEVELOPMENT MANAGER | 40 | $115,325 |
| Rodger D Curren Phd | CEO/BOARD CHAIR/SECRETARY | 15 | $42,556 |
| A Wallace Hayes | BOARD MEMBER | 0.5 | $0 |
| Richard Kouri | BOARD MEMBER | 0.5 | $0 |
| James Hoffman | BOARD MEMBER | 0.5 | $0 |
| John Fowle | BOARD MEMBER | 0.5 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202013079349302641_public.xml